Sermorelin: Growth Hormone Releasing Hormone Analog

by | Jun 9, 2015

Sermorelin is bio-identical hormone supplement that stimulates the Pituitary gland to release Growth Hormone. It is known as a Growth Hormone Releasing Hormone (GHRH). It has been shown to increase lean muscle mass, reduce body fat, increase bone density, enhance the immune system, and strengthen the heart, as well as, other organs of the body.

Sermorelin 29 Amino Acid Sequence:

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2

Sermorelin is a shortened copy of the first 29 amino acids of Growth Hormone Releasing Hormone (GHRH) that is naturally produced by the brain to stimulate pituitary production of human growth hormone. The increased quantity of human growth hormone (hGH) produced by the pituitary gland causes an increase in the production of Insulin-Like Growth Factor-1 (IGF-1) by the liver that results in the benefits of this bio-identical hormone.

How Sermorelin Works

Sermorelin stimuates the release of GH, which stimulates the release of IGF-1. The increased amount of IGF-1 in the blood stream results in an increase in metabolism and growth of new cells within the body’s organs and bones. Sermorelin has been shown to stimulate an increase in lean muscle mass, reduce body fat, increase bone density, increase collagen and the production cartilage, ligaments and tendons, enhance the immune system, and strengthen the heart and other organs of the body. Since the increased quantity of human growth hormone is produced by the body’s pituitary gland, which has an internal monitoring system, the body’s endocrine system will not allow more growth hormone to be produced by Sermorelin/GHRH stimulation of the pituitary than the body can safely process within the endocrine self-monitoring system.

The discovery of Sermorelin is considered a major breakthrough alternative to injectable Growth Hormone (GH). Injectable GH is recognized as having significant effects as an anti-aging tool, however, it is extremely expensive and must be given by daily injections for prolonged periods of time. Clinical Trials performed by Dr. Daniel Rudman in the 1980’s found that injectable GH could reverse biological age in the 60-80 year old group by as much as 20-years if administered daily over months or year. The factors that were measured during the Clinical Trials included fat to muscle ratios, skin thickness and elasticity, hair growth and density and hand grip strength, plus there were positive reports of improved libido, energy and well being levels.

Sermorelin is much less expensive than the drug copies of Growth Hormone, like Norditropin, Genitropin, etc, and it does not require daily injections to be effective. It is available in a sublingual Troche that can be taken under the tongue once daily at bedtime rather than given by injection. Sermorelin is available by prescription only from compounding pharmacies.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

13 + 5 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });